ACTU on Nasdaq
ACTUATE THERAPEUTICS, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $10.3M | $18.7M |
| General and administrative | $12.2M | $6.5M |
| Total operating expenses | $22.5M | $25.2M |
| Loss from operations | -$22.5M | -$25.2M |
| Change in estimated fair value of warrant liability | $0 | -$78.9K |
| Gain on settlement of warrants | $0 | $343.2K |
| Loss on issuance of related party convertible notes payable at fair value | $0 | -$400.0K |
| Change in estimated fair value of related party convertible notes payable | $0 | -$2.2M |
| Interest expense | -$20.2K | -$18.7K |
| Interest income | $287.7K | $222.3K |
| Total other income (expense), net | $267.5K | -$2.1M |
| Net loss | -$22.2M | -$27.3M |
| Weighted-average shares of common stock outstanding, basic | 21.0M shares | 8.4M shares |
| Weighted-average shares of common stock outstanding, diluted | 21.0M shares | 8.4M shares |
| Net loss per share attributable to common stockholders, basic | -$1.06 | -$3.26 |
| Net loss per share attributable to common stockholders, diluted | -$1.06 | -$3.26 |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $13.2M | $8.6M | |
| Prepaid assets and other current assets | $484.0K | $566.3K | |
| Total current assets | $13.6M | $9.2M | |
| Deferred offering costs and other assets | $392.5K | $110.5K | |
| Total assets | $14.0M | $9.3M | |
| Accounts payable | $1.5M | $1.9M | |
| Other accrued expenses | $3.6M | $5.9M | |
| Accrued compensation | $588.3K | $888.4K | |
| Accrued interest, current | $27.0K | $71.0K | |
| Total current liabilities | $5.7M | $8.8M | |
| Accrued interest, less current portion | $0 | $6.8K | |
| License payable | $405.0K | $405.0K | |
| Total long-term liabilities | $405.0K | $411.8K | |
| Total liabilities | $6.1M | $9.2M | |
| Preferred stock, $0.000001 par value, 10,000,000 shares authorized, no shares issued or outstanding | $0 | $0 | |
| Common stock, $0.000001 par value, 200,000,000 shares authorized, 23,245,203 and 19,531,636 shares issued and outstanding at December 31, 2025 and 2024, respectively | $23 | $20 | |
| Additional paid-in capital | $162.5M | $132.5M | |
| Accumulated deficit | -$154.6M | -$132.4M | |
| Total stockholders equity | $7.9M | $104.2K | -$99.6M |
| Total liabilities and stockholders equity | $14.0M | $9.3M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 23.2M shares | 19.5M shares | |
| Common stock, shares outstanding | 23.2M shares | 19.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$22.2M | -$27.3M |
| Stock-based compensation expense | $6.0M | $2.0M |
| Change in estimated fair value of warrant liability | $0 | $78.9K |
| Gain on settlement of warrant liability | $0 | -$343.2K |
| Loss on issuance of related party convertible notes payable at fair value | $0 | $400.0K |
| Change in estimated fair value of related party convertible notes payable | $0 | $2.2M |
| Interest accrued on license payable | $20.2K | $18.6K |
| Prepaid assets and other current assets | $82.3K | -$529.4K |
| Other assets | $110.5K | -$110.5K |
| Accounts payable | -$512.5K | -$1.5M |
| Accrued compensation | -$300.1K | $610.9K |
| Accrued interest | -$71.0K | -$71.0K |
| Other accrued expenses | -$2.4M | $2.7M |
| Net cash used in operating activities | -$19.2M | -$21.8M |
| Proceeds from issuance of shares of common stock under underwritten public offering, net of underwriting discounts and offering costs | $15.6M | $0 |
| Proceeds from issuance of shares of common stock under June 2025 Private Placement, net | $4.6M | $0 |
| Proceeds from issuance of shares of common stock under the Committed Equity Facility, net | $3.8M | $0 |
| Proceeds from the exercise of stock options | $34.1K | $0 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | $0 | $24.0M |
| Payment of offering costs related to initial public offering | $0 | -$1.9M |
| Proceeds from issuance of related party short-term loan | $0 | $200.0K |
| Payment of related party short-term loan | $0 | -$200.0K |
| Proceeds from issuances of related party convertible notes payable | $0 | $5.5M |
| Deferred offering costs | -$302.8K | $0 |
| Net cash provided by financing activities | $23.7M | $27.5M |
| Net change in cash and cash equivalents | $4.5M | $5.7M |
| Cash paid for interest | $71.0K | $71.0K |
| Cash paid for income taxes | $800 | $800 |
| Conversion of redeemable convertible preferred stock into common stock upon initial public offering | $0 | $94.2M |
| Reclassification of warrant liability to equity upon exchange of not in-the-money Series B and Series C Redeemable Convertible Preferred Stock Warrants for warrants to purchase common stock | $0 | $485.2K |
| Exercise of in-the-money warrants to purchase redeemable convertible preferred stock and conversion into common stock upon initial public offering | $0 | $238.5K |
| Conversion of related party convertible notes payable into common stock upon initial public offering | $0 | $8.1M |
| Deferred offering costs, unpaid and accrued | $115.5K | $0 |
| Deferred offering costs charged against Committed Equity Facility | $25.9K | $0 |
Recent filings
- Oct 14, 2026S-1/A FORM S-1 AMENDMENT
- Oct 8, 2026FWP FREE WRITING PROSPECTUS
- Oct 6, 2026S-1 REGISTRATION STATEMENT
- Aug 14, 202610-Q FORM 10-Q FOR JUN 2026
- Aug 14, 20264
- Jul 17, 20268-K CURRENT REPORT
- Jun 8, 2026DRS
- May 22, 20264
- May 22, 20264
- May 22, 20264
- May 22, 20264
- May 22, 20264
- May 22, 20264
- May 22, 20264
- May 22, 20268-K CURRENT REPORT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6